AOUT Q1 2026 Earnings Significant EPS Beat Despite Stock Decline Ovid Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Supports Biotechs Cash Discipline Marker Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Progresses OppFi Q1 2026 Earnings EPS Beat Drives Positive Momentum Despite Stock Pullback Voyager Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Market Response Medical Properties Trust Inc MPT Q1 2026 Earnings EPS Surges Past Estimates with 65 Beat